SCHEMBL5453319

SCHEMBL5453319

CCOC(=O)c1c(NC(=O)C(C)(C)C)sc2c1CCOC2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.53
ALDH1A1 P00352 6/20 0.53
LMNA P02545 1/20 0.53
TSHR P16473 5/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
HSD17B10 Q99714 3/20 0.51
ANO1 Q5XXA6 3/20 0.51
CXCR2 P25025 2/20 0.51
ALOX15 P16050 2/20 0.51
MAPK1 P28482 1/20 0.51
CNR2 P34972 2/20 0.50
KDM4E B2RXH2 4/20 0.49
KMT2A Q03164 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
NPSR1 Q6W5P4 2/20 0.49
GAA P10253 1/20 0.49
PTPRC P08575 1/20 0.49
PTPN2 P17706 1/20 0.49
PTPN1 P18031 1/20 0.49
PTPRB P23467 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5460524 0.87 ALDH1A1 (0.56) MAPTALDH1A1LMNATSHRSMN1; SMN2
SCHEMBL5458496 0.84 ALDH1A1 (0.56) MAPTALDH1A1LMNATSHRSMN1; SMN2
SCHEMBL5450569 0.84 KMT2A (0.69) MAPTALDH1A1LMNATSHRSMN1; SMN2
SCHEMBL5467525 0.84 ALDH1A1 (0.53) MAPTALDH1A1LMNATSHRSMN1; SMN2
SCHEMBL16210336 0.83 MAPT (0.71) MAPTALDH1A1LMNATSHRSMN1; SMN2
SCHEMBL4080930 0.83 CNR2 (0.69) MAPTALDH1A1LMNATSHRSMN1; SMN2
SCHEMBL5451879 0.83 ALDH1A1 (0.52) MAPTALDH1A1LMNATSHRSMN1; SMN2
SCHEMBL5458226 0.83 ALDH1A1 (0.52) MAPTALDH1A1LMNATSHRSMN1; SMN2
SCHEMBL5457865 0.82 MAPT (0.51) MAPTALDH1A1LMNATSHRSMN1; SMN2
SCHEMBL5457868 0.82 MAPT (0.51) MAPTALDH1A1LMNATSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 MAPT 21/4885ALDH1A1 1153/4885LMNA 3232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.